Note
3 – Earnings (Loss) Per Common Share
Net
loss per common and diluted share were calculated as follows for the year ended April 30, 2025 and 2024:
Schedule
of Earnings Per Share
| | |
Year
Ended
April 30, 2025 | | |
Year
Ended
April 30, 2024 | |
| Net loss attributable to common
stockholders – basic | |
$ | (28,301,325 | ) | |
$ | (4,986,317 | ) |
| Adjustments to net loss | |
| — | | |
| — | |
| Net loss attributable
to common stockholders – diluted | |
$ | (28,301,325 | ) | |
$ | (4,986,317 | ) |
| | |
| | | |
| | |
| Weighted average common shares outstanding - basic | |
| 1,387,666 | | |
| 172,937 | |
| Effect of dilutive securities | |
| — | | |
| — | |
| Weighted average common shares outstanding
– diluted | |
| 1,387,666 | | |
| 172,937 | |
| | |
| | | |
| | |
| Loss per common share - basic | |
$ | (20.39 | ) | |
$ | (28.83 | ) |
| Loss per common share - diluted | |
$ | (20.39 | ) | |
$ | (28.83 | ) |
Outstanding
vested warrants to purchase 556,973 and 614,533 shares of common stock are not included in the calculation of earnings per share for
the years ended April 30, 2025 and 2024, respectively, because their effect is anti-dilutive.
Outstanding
vested options to purchase 16,943 and 9,889 shares of common stock are not included in the calculation of earnings per share for the
years ended April 30, 2025 and 2024, respectively, because their effect is anti-dilutive.
|